Last updated: 21 June 2019 at 2:31am EST

Jorma Routti Net Worth




The estimated Net Worth of Jorma Routti is at least $64.6 millier dollars as of 26 March 2019. Jorma Routti owns over 30,000 units of FibroGen Inc stock worth over $64,616 and over the last 10 years Jorma sold FGEN stock worth over $0.

Jorma Routti FGEN stock SEC Form 4 insiders trading

Jorma has made over 11 trades of the FibroGen Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Jorma exercised 30,000 units of FGEN stock worth $682,500 on 26 March 2019.

The largest trade Jorma's ever made was exercising 30,000 units of FibroGen Inc stock on 26 March 2019 worth over $682,500. On average, Jorma trades about 7,176 units every 70 days since 2014. As of 26 March 2019 Jorma still owns at least 161,540 units of FibroGen Inc stock.

You can see the complete history of Jorma Routti stock trades at the bottom of the page.



What's Jorma Routti's mailing address?

Jorma's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.

Insiders trading at FibroGen Inc

Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff et Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.



What does FibroGen Inc do?

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.



What does FibroGen Inc's logo look like?

FibroGen Inc logo

Complete history of Jorma Routti stock trades at FibroGen Inc

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
26 Mar 2019 Jorma Routti
Directeur
Exercice d'option 30,000 $22.75 $682,500
26 Mar 2019
161,540
10 Sep 2018 Jorma Routti
Directeur
Exercice d'option 6,000 $18.34 $110,040
10 Sep 2018
137,540
9 Aug 2018 Jorma Routti
Directeur
Exercice d'option 6,000 $18.00 $108,000
9 Aug 2018
137,540
9 Jul 2018 Jorma Routti
Directeur
Exercice d'option 6,000 $18.00 $108,000
9 Jul 2018
137,540
11 Jun 2018 Jorma Routti
Directeur
Exercice d'option 6,000 $9.78 $58,680
11 Jun 2018
137,540
9 May 2018 Jorma Routti
Directeur
Exercice d'option 6,000 $9.78 $58,680
9 May 2018
133,840
9 Apr 2018 Jorma Routti
Directeur
Exercice d'option 6,000 $5.95 $35,700
9 Apr 2018
133,840
14 Feb 2018 Jorma Routti
Directeur
Exercice d'option 12,000 $3.50 $42,000
14 Feb 2018
133,840
30 Nov 2017 Jorma Routti
Directeur
Exercice d'option 12,000 $2.90 $34,800
30 Nov 2017
133,840
31 Aug 2017 Jorma Routti
Directeur
Exercice d'option 12,000 $3.60 $43,200
31 Aug 2017
133,840
28 Dec 2015 Jorma Routti
Directeur
Exercice d'option 20,000 $3.22 $64,400
28 Dec 2015
127,840


FibroGen Inc executives and stock owners

FibroGen Inc executives and other stock owners filed with the SEC include: